Progression independent of relapsing biology in multiple sclerosis: a real-word study
Progression independent of relapse activity (PIRA) implies disability progression in people with relapsing–remitting multiple sclerosis (RRMS) secondary to neurodegeneration. Mechanistically and biologically PIRA could impact the traditional distinction between progressive and relapsing-MS. Herein,...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-05-01
|
| Series: | Frontiers in Neurology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fneur.2025.1595929/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849717038996520960 |
|---|---|
| author | Heather Y. F. Yong Heather Y. F. Yong Carlos Camara-Lemarroy Carlos Camara-Lemarroy |
| author_facet | Heather Y. F. Yong Heather Y. F. Yong Carlos Camara-Lemarroy Carlos Camara-Lemarroy |
| author_sort | Heather Y. F. Yong |
| collection | DOAJ |
| description | Progression independent of relapse activity (PIRA) implies disability progression in people with relapsing–remitting multiple sclerosis (RRMS) secondary to neurodegeneration. Mechanistically and biologically PIRA could impact the traditional distinction between progressive and relapsing-MS. Herein, we estimated progression independent of relapsing biology (PIRB) in a cohort of 823 participants with clinically-isolated syndrome/RRMS in Calgary, Canada using a modified criterion [excluding relapses, inflammatory MRI activity, interim disability worsening/improvement over the observation period, and progression secondary to alternative causes including formal conversion to secondary-progressive MS]. PIRB was rare and rates remained consistent across disease-modifying therapies (3.75% dimethyl fumarate, 3.67% fingolimod, 3.72% ocrelizumab, 3.52% minocycline) despite varied rates of disability progression. PIRB may offer a practical alternative to the concept of PIRA. |
| format | Article |
| id | doaj-art-c9e30d8adc4f4e72839ec7ba326fbd74 |
| institution | DOAJ |
| issn | 1664-2295 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Neurology |
| spelling | doaj-art-c9e30d8adc4f4e72839ec7ba326fbd742025-08-20T03:12:47ZengFrontiers Media S.A.Frontiers in Neurology1664-22952025-05-011610.3389/fneur.2025.15959291595929Progression independent of relapsing biology in multiple sclerosis: a real-word studyHeather Y. F. Yong0Heather Y. F. Yong1Carlos Camara-Lemarroy2Carlos Camara-Lemarroy3Department of Clinical Neurosciences, University of Calgary, Calgary, AB, CanadaCumming School of Medicine, University of Calgary, Calgary, AB, CanadaDepartment of Clinical Neurosciences, University of Calgary, Calgary, AB, CanadaCumming School of Medicine, University of Calgary, Calgary, AB, CanadaProgression independent of relapse activity (PIRA) implies disability progression in people with relapsing–remitting multiple sclerosis (RRMS) secondary to neurodegeneration. Mechanistically and biologically PIRA could impact the traditional distinction between progressive and relapsing-MS. Herein, we estimated progression independent of relapsing biology (PIRB) in a cohort of 823 participants with clinically-isolated syndrome/RRMS in Calgary, Canada using a modified criterion [excluding relapses, inflammatory MRI activity, interim disability worsening/improvement over the observation period, and progression secondary to alternative causes including formal conversion to secondary-progressive MS]. PIRB was rare and rates remained consistent across disease-modifying therapies (3.75% dimethyl fumarate, 3.67% fingolimod, 3.72% ocrelizumab, 3.52% minocycline) despite varied rates of disability progression. PIRB may offer a practical alternative to the concept of PIRA.https://www.frontiersin.org/articles/10.3389/fneur.2025.1595929/fullprogression independent of relapse biologyprogression independent of relapse activityPIRAmultiple sclerosisMSrelapsing remitting multiple sclerosis |
| spellingShingle | Heather Y. F. Yong Heather Y. F. Yong Carlos Camara-Lemarroy Carlos Camara-Lemarroy Progression independent of relapsing biology in multiple sclerosis: a real-word study Frontiers in Neurology progression independent of relapse biology progression independent of relapse activity PIRA multiple sclerosis MS relapsing remitting multiple sclerosis |
| title | Progression independent of relapsing biology in multiple sclerosis: a real-word study |
| title_full | Progression independent of relapsing biology in multiple sclerosis: a real-word study |
| title_fullStr | Progression independent of relapsing biology in multiple sclerosis: a real-word study |
| title_full_unstemmed | Progression independent of relapsing biology in multiple sclerosis: a real-word study |
| title_short | Progression independent of relapsing biology in multiple sclerosis: a real-word study |
| title_sort | progression independent of relapsing biology in multiple sclerosis a real word study |
| topic | progression independent of relapse biology progression independent of relapse activity PIRA multiple sclerosis MS relapsing remitting multiple sclerosis |
| url | https://www.frontiersin.org/articles/10.3389/fneur.2025.1595929/full |
| work_keys_str_mv | AT heatheryfyong progressionindependentofrelapsingbiologyinmultiplesclerosisarealwordstudy AT heatheryfyong progressionindependentofrelapsingbiologyinmultiplesclerosisarealwordstudy AT carloscamaralemarroy progressionindependentofrelapsingbiologyinmultiplesclerosisarealwordstudy AT carloscamaralemarroy progressionindependentofrelapsingbiologyinmultiplesclerosisarealwordstudy |